Therapeutic Agent for Osteoporosis Using a Retinoid X Receptor-Related Compound
    1.
    发明申请
    Therapeutic Agent for Osteoporosis Using a Retinoid X Receptor-Related Compound 审中-公开
    使用类视黄醇X受体相关化合物治疗骨质疏松症的治疗剂

    公开(公告)号:US20090270612A1

    公开(公告)日:2009-10-29

    申请号:US12065994

    申请日:2006-09-04

    IPC分类号: C07D243/10

    CPC分类号: A61K31/5513

    摘要: It is an object of the present invention to provide a novel therapeutic agent for osteoporosis.HX531 is utilized, which is synthesized as a retinoid X receptor antagonist and has an activity in inhibiting a differentiation into adipocytes. Furthermore, any dosage form containing HX531 as an effective component can be used.

    摘要翻译: 本发明的目的是提供一种用于骨质疏松症的新型治疗剂。 使用HX531,其被合成为类视色素X受体拮抗剂,并且具有抑制分化成脂肪细胞的活性。 此外,可以使用含有HX531作为有效成分的任何剂型。